Garber Alan M 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Jul 17, 2026
Research Summary
AI-generated summary of this filing
Vertex (VRTX) Director Alan Garber Receives Award 31.56 Shares
What Happened
- Alan M. Garber, a director of Vertex Pharmaceuticals (VRTX), was granted 31.56 deferred stock units on 2026-07-15. The units are valued at $475.28 each, for a total grant value of $15,000. This transaction is coded as an award/acquisition (derivative), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (timely filing).
- Grant: 31.56 deferred stock units at $475.28 per unit; total value $15,000.
- Shares owned after transaction: not specified in the filing.
- Footnote: Each deferred stock unit equals one share of common stock and will be paid out in common stock upon the earliest of (i) termination of Dr. Garber’s board service, (ii) a change of control, or (iii) Dr. Garber’s disability or death.
- Transaction type: Award/derivative (code A) — not a purchase (P) or sale (S).
Context
- Deferred stock units are a common form of director compensation and represent a future right to receive shares rather than an immediate market purchase. Such awards do not by themselves indicate the insider’s view on the company’s stock price; they reflect compensation terms and vesting/settlement conditions.
Insider Transaction Report
Form 4
Garber Alan M
Director
Transactions
- Award
Deferred Stock Units
[F1]2026-07-15$475.28/sh+31.56$15,000→ 65.458 total→ Common Stock (31.56 underlying)
Footnotes (1)
- [F1]Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death.
Signature
/s/ Christiana Stevenson, Attorney-in-Fact|2026-07-17